INCY News and Press, Incyte Corporation From 04/29/21

Hengrui USA, a unit of Jiangsu Hengrui Pharmaceuticals announced that the FDA has granted the orphan drug designation for Camrelizumab in the treatment of hepatocellular carcinoma ("HCC"), the commonest form of primary liver cancer.An anti-PD-1 antibody, Camrelizumab has won Ch...

The European Medicines Agency (“EMA”) has started to review a marketing application to expand the use of Olumiant (baricitinib) for COVID-19 in hospitalized patients aged more than 10 years who require supplemental oxygen.In 2009, Eli Lilly ([[LLY]] +0.6%) and Incyte (...

Incyte ([[INCY]] +1.3%) has announced additional findings from two Phase 3 studies evaluating ruxolitinib cream, an investigational JAK1/JAK2 inhibitor for patients with atopic dermatitis ("AD").A few years ago, Incyte acquired the rights to develop and commercialize ruxolitinib fro...

OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses - Extended safety analysis across eight studies helps further define the known safety profile of OLUMIANT 2-mg in atopic d...

- Presentations will be available on demand as part of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX) Incyte (Nasdaq:INCY) today announced findings from three pooled analyses of its randomized, double-blind, vehicle-controlled Phase 3 studies &...

- Presentations will be available on demand as part of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX) Incyte (Nasdaq:INCY) today announced findings from two analyses of its randomized, dose-ranging, vehicle-controlled Phase 2 study evaluating r...

Cathie Wood is betting on a genomic revolution because she believes it will be the next big industry disrupting development. We believe Wood’s favorite stocks, Vertex Pharmaceuticals Incorporated (VRTX) and Incyte Corporation (INCY), have attractive upside potential and are ideal inves...

More than 14 abstracts, including new findings from Incyte’s clinical trial programs for ruxolitinib cream in patients with vitiligo and atopic dermatitis, to be presented Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its dermatol...

Eli Lilly (LLY) and Incyte (INCY) announce results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata ((AA)).The data are consistent with findings from the first Phase 3 clinical tr...

Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study - Results from two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth across both baricitinib dosing groups, compared to pl...